We can now provide neurons and astrocytes with defined MAPT haplotypes, offering researchers access to cells selected by genetic background that is directly relevant to tau biology and neurodegenerative disease research.

What’s new?

• MAPT H1/H2 genotyping using SNP rs8070723
• H1c sub-haplotype identification via SNP rs242557
• Multiple donors with different MAPT genotypes are available

Why this matters? 

MAPT genotypes are associated with differences in tau expression and behavior across donors. Cells carrying the H1c sub-haplotype tend to show higher tau expression or greater responsiveness under stress, while H1/H2 backgrounds are generally linked to lower tau-related activity. Selecting MAPT-typed neurons or astrocytes allows researchers to account for genetic variability, helping improve reproducibility and interpretation of tau-related experimental results. Having access to human primary neurons and astrocytes with known MAPT status allows for: 

• More controlled experimental design
• Reduced donor-to-donor variability
• Improved interpretation of tau-related phenotypes and drug responses

Genotype selection helps control genetic variability and interpret experimental outcomes; observed effects may depend on assay conditions.